UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042481
Receipt number R000048368
Scientific Title Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.
Date of disclosure of the study information 2020/11/18
Last modified on 2023/03/20 15:10:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.

Acronym

Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.

Scientific Title

Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.

Scientific Title:Acronym

Investigating glycemic controls achieved in one year after discharge among type2 diabetic inpatients who received semaglutide via protecting beta-cell function.

Region

Japan


Condition

Condition

type2 diabetes

Classification by specialty

Medicine in general Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate whether type2 diabetic inpatients who received semaglutide achieved better glycemic controls via protecting beta-cell function compared with those who did not.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

HbA1c levels in one year after discharge.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking

YES

Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Semaglutide group:
In hospitalization, participants receive semaglutide 0.25mg once a week.
After discharge, participants receive semaglutide 0.50mg once a week in 12 weeks.
After 12 weeks of discharge, appropriate treatment will be given by judgement of the attending physician.

Interventions/Control_2

Control group:
Paticipants does not inject semaglutide until 12 weeks later discharge.
After 12 weeks of discharge, appropriate treatment will be given by judgement of the attending physician.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) type2 diabetic inpatients
2) Patients who are over 20 years or older
3) Patinets never using GLP-1 receptor agonists
4) Diabetes duration within 10 years
5) Patients with the written informed consent

Key exclusion criteria

1) Patients with severe liver dysfunction
2) Patients with severe renal dysfunction(eGFR<30ml/min/1.73)
3) Patients with fasting serum CPR <0.5 or postprandial serum CPR <1.0
4) Patinet with diabetic ketoacidosis
5) Patient with infection
6) Patients taking steroid
7) Patients with malignant tumor currently undergoing treatment
8) Pregnant or lactating woman
9) Other patients who are judged to be unsuitable as subjects by the judgment of a doctor

Target sample size

80


Research contact person

Name of lead principal investigator

1st name Taichi
Middle name
Last name Minami

Organization

Saiseikai Yokohamashi Nanbu Hospital

Division name

Department of Diabetes and Endocrinology

Zip code

234-0054

Address

3-2-10 Konandai, Konan-ku, Yokohama, Kanagawa, Japan

TEL

045-832-1111

Email

ksqdd034@yahoo.co.jp


Public contact

Name of contact person

1st name Taichi
Middle name
Last name Minami

Organization

Saiseikai Yokohamashi Nanbu Hospital

Division name

Department of Diabetes and Endocrinology

Zip code

234-0054

Address

3-2-10 Konandai, Konan-ku, Yokohama, Kanagawa, Japan

TEL

045-832-1111

Homepage URL


Email

ksqdd034@yahoo.co.jp


Sponsor or person

Institute

Saiseikai Yokohamashi Nanbu Hospital

Institute

Department

Personal name



Funding Source

Organization

Saiseikai Yokohamashi Nanbu Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

none

Name of secondary funder(s)

none


IRB Contact (For public release)

Organization

Saiseikai Yokohamashi Nanbu Hospital

Address

3-2-10 Konandai, Konan-ku, Yokohama, Kanagawa, Japan

Tel

045-832-1111

Email

soumu01@nanbu.saiseikai.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 11 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2020 Year 09 Month 28 Day

Date of IRB

2020 Year 10 Month 06 Day

Anticipated trial start date

2020 Year 11 Month 04 Day

Last follow-up date

2022 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 11 Month 17 Day

Last modified on

2023 Year 03 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048368


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name